Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure

SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced that following a re-examination...

Related Keywords

United Kingdom ,Grosshansdorf ,Schleswig Holstein ,Germany ,Switzerland ,Martin Reck ,Alan Sandler ,Nasdaq ,Twitter ,Committee For Medicinal Products Human Use ,Healthcare Products Regulatory Agency ,Exchange Commission ,European Medicine Agency ,Linkedin ,Mirati Therapeutics Inc ,Prnewswire Mirati Therapeutics Inc ,European Commission ,European Union ,Facebook ,Mirati Therapeutic Inc ,Bristol Myers Squibb Company ,Medicinal Products ,Human Use ,Mirati Therapeutics ,Lung Clinic Grosshansdorf ,Mirati Therapeutic ,Bristol Myers Squibb ,Therapeutic Susceptibility ,Mutant Cancers ,Mouse Models ,Brain Metastases ,Preclinical Models ,Clinical Data ,Mutant Non Small Cell Lung ,Clin Cancer ,Published April ,Markets ,